6cqn › Citations

CD4+ T cell-mediated HLA class II cross-restriction in HIV controllers.

Galperin M, Farenc C, Mukhopadhyay M, Jayasinghe D, Decroos A, Benati D, Tan LL, Ciacchi L, Reid HH, Rossjohn J, Chakrabarti LA, Gras S
Sci Immunol 3 (2018)
Related entries: 6cph, 6cpl, 6cpn, 6cpo, 6cqj, 6cql, 6cqq, 6cqr

Cited: 34 times
EuropePMC logo PMID: 29884618

Abstract

Rare individuals, termed HIV controllers, spontaneously control HIV infection by mounting efficient T cell responses against the virus. Protective CD4+ T cell responses from HIV controllers involve high-affinity public T cell receptors (TCRs) recognizing an immunodominant capsid epitope (Gag293) presented by a remarkably broad array of human leukocyte antigen (HLA) class II molecules. Here, we determine the structures of a prototypical public TCR bound to HLA-DR1, HLA-DR11, and HLA-DR15 molecules presenting the Gag293 epitope. TCR recognition was driven by contacts with the Gag293 epitope, a feature that underpinned the extensive HLA cross-restriction. These high-affinity TCRs promoted mature immunological synapse formation and cytotoxic capacity in both CD4+ and CD8+ T cells. The public TCRs suppressed HIV replication in multiple genetic backgrounds ex vivo, emphasizing the functional advantage conferred by broad HLA class II cross-restriction.

Articles - 6cqn mentioned but not cited (1)

  1. Genome-wide pharmacogenetics of anti-drug antibody response to bococizumab highlights key residues in HLA DRB1 and DQB1. Chasman DI, Hyde CL, Giulianini F, Danning RD, Wang EQ, Hickling T, Ridker PM, Loomis AK. Sci Rep 12 4266 (2022)


Reviews citing this publication (8)

  1. The Many Faces of CD4+ T Cells: Immunological and Structural Characteristics. Chatzileontiadou DSM, Sloane H, Nguyen AT, Gras S, Grant EJ. Int J Mol Sci 22 E73 (2020)
  2. T Cell Immunity to Bacterial Pathogens: Mechanisms of Immune Control and Bacterial Evasion. Shepherd FR, McLaren JE. Int J Mol Sci 21 E6144 (2020)
  3. Role of CD4+ T Cells in the Control of Viral Infections: Recent Advances and Open Questions. Kervevan J, Chakrabarti LA. Int J Mol Sci 22 E523 (2021)
  4. The role of T-cell immunity in COVID-19 severity amongst people living with type II diabetes. Tong ZWM, Grant E, Gras S, Wu M, Smith C, Barrett HL, Gallo LA, Short KR. FEBS J 288 5042-5054 (2021)
  5. Immune Literacy: Reading, Writing, and Editing Adaptive Immunity. Csepregi L, Ehling RA, Wagner B, Reddy ST. iScience 23 101519 (2020)
  6. Understanding the CD8 T-cell response in natural HIV control. Boppana S, Goepfert P. F1000Res 7 F1000 Faculty Rev-985 (2018)
  7. Current Views about the Inflammatory Damage Triggered by Bacterial Superantigens and Experimental Attempts to Neutralize Superantigen-Mediated Toxic Effects with Natural and Biological Products. Santacroce L, Topi S, Charitos IA, Lovero R, Luperto P, Palmirotta R, Jirillo E. Pathophysiology 31 18-31 (2024)
  8. Protective HLA-B57: T cell and natural killer cell recognition in HIV infection. Lobos CA, Downing J, D'Orsogna LJ, Chatzileontiadou DSM, Gras S. Biochem Soc Trans 50 1329-1339 (2022)

Articles citing this publication (25)

  1. HLA-DR15 Molecules Jointly Shape an Autoreactive T Cell Repertoire in Multiple Sclerosis. Wang J, Jelcic I, Mühlenbruch L, Haunerdinger V, Toussaint NC, Zhao Y, Cruciani C, Faigle W, Naghavian R, Foege M, Binder TMC, Eiermann T, Opitz L, Fuentes-Font L, Reynolds R, Kwok WW, Nguyen JT, Lee JH, Lutterotti A, Münz C, Rammensee HG, Hauri-Hohl M, Sospedra M, Stevanovic S, Martin R. Cell 183 1264-1281.e20 (2020)
  2. A common allele of HLA is associated with asymptomatic SARS-CoV-2 infection. Augusto DG, Murdolo LD, Chatzileontiadou DSM, Sabatino JJ, Yusufali T, Peyser ND, Butcher X, Kizer K, Guthrie K, Murray VW, Pae V, Sarvadhavabhatla S, Beltran F, Gill GS, Lynch KL, Yun C, Maguire CT, Peluso MJ, Hoh R, Henrich TJ, Deeks SG, Davidson M, Lu S, Goldberg SA, Kelly JD, Martin JN, Vierra-Green CA, Spellman SR, Langton DJ, Dewar-Oldis MJ, Smith C, Barnard PJ, Lee S, Marcus GM, Olgin JE, Pletcher MJ, Maiers M, Gras S, Hollenbach JA. Nature 620 128-136 (2023)
  3. GIANA allows computationally-efficient TCR clustering and multi-disease repertoire classification by isometric transformation. Zhang H, Zhan X, Li B. Nat Commun 12 4699 (2021)
  4. Microbial peptides activate tumour-infiltrating lymphocytes in glioblastoma. Naghavian R, Faigle W, Oldrati P, Wang J, Toussaint NC, Qiu Y, Medici G, Wacker M, Freudenmann LK, Bonté PE, Weller M, Regli L, Amigorena S, Rammensee HG, Walz JS, Brugger SD, Mohme M, Zhao Y, Sospedra M, Neidert MC, Martin R. Nature 617 807-817 (2023)
  5. Primary EBV Infection Induces an Acute Wave of Activated Antigen-Specific Cytotoxic CD4+ T Cells. Meckiff BJ, Ladell K, McLaren JE, Ryan GB, Leese AM, James EA, Price DA, Long HM. J Immunol 203 1276-1287 (2019)
  6. Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses. Brentville VA, Metheringham RL, Daniels I, Atabani S, Symonds P, Cook KW, Vankemmelbeke M, Choudhury R, Vaghela P, Gijon M, Meiners G, Krebber WJ, Melief CJM, Durrant LG. J Immunother Cancer 8 e000560 (2020)
  7. Mechanical forces impair antigen discrimination by reducing differences in T-cell receptor/peptide-MHC off-rates. Pettmann J, Awada L, Różycki B, Huhn A, Faour S, Kutuzov M, Limozin L, Weikl TR, van der Merwe PA, Robert P, Dushek O. EMBO J 42 e111841 (2023)
  8. Low CCR5 expression protects HIV-specific CD4+ T cells of elite controllers from viral entry. Claireaux M, Robinot R, Kervevan J, Patgaonkar M, Staropoli I, Brelot A, Nouël A, Gellenoncourt S, Tang X, Héry M, Volant S, Perthame E, Avettand-Fenoël V, Buchrieser J, Cokelaer T, Bouchier C, Ma L, Boufassa F, Hendou S, Libri V, Hasan M, Zucman D, de Truchis P, Schwartz O, Lambotte O, Chakrabarti LA. Nat Commun 13 521 (2022)
  9. Single-Cell Transcriptomic Profiling of MAIT Cells in Patients With COVID-19. Shi J, Zhou J, Zhang X, Hu W, Zhao JF, Wang S, Wang FS, Zhang JY. Front Immunol 12 700152 (2021)
  10. Immune Correlates of Natural HIV Elite Control and Simultaneous HCV Clearance-Supercontrollers. Dominguez-Molina B, Ferrando-Martinez S, Tarancon-Diez L, Hernandez-Quero J, Genebat M, Vidal F, Muñoz-Fernandez MA, Leal M, Koup R, Ruiz-Mateos E. Front Immunol 9 2897 (2018)
  11. CD4+ T Cells Recognize Conserved Influenza A Epitopes through Shared Patterns of V-Gene Usage and Complementary Biochemical Features. Greenshields-Watson A, Attaf M, MacLachlan BJ, Whalley T, Rius C, Wall A, Lloyd A, Hughes H, Strange KE, Mason GH, Schauenburg AJ, Hulin-Curtis SL, Geary J, Chen Y, Lauder SN, Smart K, Vijaykrishna D, Grau ML, Shugay M, Andrews R, Dolton G, Rizkallah PJ, Gallimore AM, Sewell AK, Godkin AJ, Cole DK. Cell Rep 32 107885 (2020)
  12. Escherichiacoli-Specific CD4+ T Cells Have Public T-Cell Receptors and Low Interleukin 10 Production in Crohn's Disease. Uchida AM, Boden EK, James EA, Shows DM, Konecny AJ, Lord JD. Cell Mol Gastroenterol Hepatol 10 507-526 (2020)
  13. Measuring Antiviral Capacity of T Cell Responses to Adenovirus. Keib A, Mei YF, Cicin-Sain L, Busch DH, Dennehy KM. J Immunol 202 618-624 (2019)
  14. TScan-II: A genome-scale platform for the de novo identification of CD4+ T cell epitopes. Dezfulian MH, Dezfulian MH, Kula T, Pranzatelli T, Kamitaki N, Meng Q, Khatri B, Perez P, Xu Q, Chang A, Kohlgruber AC, Leng Y, Jupudi AA, Joachims ML, Chiorini JA, Lessard CJ, Farris AD, Muthuswamy SK, Warner BM, Elledge SJ. Cell 186 5569-5586.e21 (2023)
  15. HIV-1-Infected CD4+ T Cells Present MHC Class II-Restricted Epitope via Endogenous Processing. Addison MM, Ellis GI, Leslie GJ, Zawadzky NB, Riley JL, Hoxie JA, Eisenlohr LC. J Immunol 209 864-873 (2022)
  16. HLA-A and HLA-DRB1 may play a unique role in ovarian teratoma-associated anti-N-methyl-D-aspartate receptor encephalitis. Zhao X, Li J, Zhu Q, Liang G, Xia W, He X, Zhu C, Qi H, Deng B, Chen X, Zhang J. Reprod Biol Endocrinol 18 107 (2020)
  17. Impact of HLA-DR Antigen Binding Cleft Rigidity on T Cell Recognition. Szeto C, Bloom JI, Sloane H, Lobos CA, Fodor J, Jayasinghe D, Chatzileontiadou DSM, Grant EJ, Buckle AM, Gras S. Int J Mol Sci 21 E7081 (2020)
  18. Structural definition of HLA class II-presented SARS-CoV-2 epitopes reveals a mechanism to escape pre-existing CD4+ T cell immunity. Chen Y, Mason GH, Scourfield DO, Greenshields-Watson A, Haigh TA, Sewell AK, Long HM, Gallimore AM, Rizkallah P, MacLachlan BJ, Godkin A. Cell Rep 42 112827 (2023)
  19. Protective T cell receptor identification for orthotopic reprogramming of immunity in refractory virus infections. Stief TA, Kaeuferle T, Müller TR, Döring M, Jablonowski LM, Schober K, Feucht J, Dennehy KM, Willier S, Blaeschke F, Handgretinger R, Lang P, Busch DH, Feuchtinger T. Mol Ther 30 198-208 (2022)
  20. Safety and durability of AGT103-T autologous T cell therapy for HIV infection in a Phase 1 trial. Muvarak N, Li H, Lahusen T, Galvin JA, Kumar PN, Pauza CD, Bordon J. Front Med (Lausanne) 9 1044713 (2022)
  21. Competition-Based Cell Assay Employing Soluble T Cell Receptors to Assess MHC Class II Antigen Processing and Presentation. Tasker C, Patel J, Jawa V, Maamary J. AAPS J 23 26 (2021)
  22. A unique dysregulation pattern of lipid metabolism and immune responses in patients with omicron SARS-CoV-2 recurrence. Liu F, Sun R, Li J, Huang W, Huang J, Bao J. QJM 115 640-643 (2022)
  23. Proof-of-Concept Analysis of B Cell Receptor Repertoire in COVID-19 Patients Undergoing ECMO by Single-Cell V(D)J and Gene Expression Sequencing. Gallo A, Cuscino N, Carcione C, Busà R, Conaldi PG, Bulati M. Curr Issues Mol Biol 45 1471-1482 (2023)
  24. Proteomics of Serum Samples for the Exploration of the Pathological Mechanism of Obstetric Antiphospholipid Syndrome. Zhang Y, Jin S, Tian W, Shi D, Chen Y, Cui L, Zheng J. J Proteome Res 23 289-300 (2024)
  25. Structural basis of the TCR-pHLA complex provides insights into the unconventional recognition of CDR3β in TCR cross-reactivity and alloreactivity. San D, Lei J, Liu Y, Jing B, Ye X, Wei P, Paek C, Yang Y, Zhou J, Chen P, Wang H, Chen Y, Yin L. Cell Insight 2 100076 (2023)


Quick links